ERBB2 and carcinoma: Neither in HPV-positive nor in HPV-negative carcinomas HER2/neu overexpression was associated with any clinicopathological factors, including tumor size, lymph vessel invasion, vascular invasion, and lymph node metastasis (data not shown).